Cash per share
$4.09
June cash ÷ 58.1m reported shares
Capricor’s FDA Delay Leaves a $2.20-a-Share Bet on Deramiocel
Capricor Therapeutics, Inc. ended Friday with only about $2.20 per share of equity value above its June cash. That preliminary figure frames the wager on deramiocel after regulators delayed their decision.
NASDAQ: CAPR · Event-driven biotech
Deramiocel: more review, more runway risk
Market data through August 21, 2026, 4:00 p.m. EDT · Financial data through June 30, 2026
$6.29
−8.04% Friday
After hours: $6.38 at 7:59 p.m. EDT
Price above cash
$2.20
Preliminary; not liquidation value
Market cap
$365.5m
Friday close × June share count
Target range
$2–$28
Consensus Hold · median $6
Six-session repricing
August 14 volume reached 66.3m shares. Friday volume was 8.3m, while the close sat 5.4% below August 14.
Regulatory evidence stack
Bar lengths are visual emphasis, not probabilities. The committee vote was advisory and nonbinding.
Cash versus burn
| Metric | 2026 | Comparison |
|---|---|---|
| Cash & securities | $237.9m | −$80.2m in H1 |
| Q2 operating expense | $42.9m | +55.0% YoY |
| Q2 net loss | $40.7m | +57.2% YoY |
| Runway at H1 loss pace | ~19 months | Preliminary |
Company guidance: resources fund at least the next 12 months.
Analyst recommendation map
| Firm | Action | Rating | Target | Versus $6.29 |
|---|---|---|---|---|
| Cantor Fitzgerald | Upgrade | Buy | $28 | +345% |
| Piper Sandler | Maintain | Hold | $2 | −68% |
| B. Riley | Maintain | Hold | $5 | −21% |
| Consensus | — | Hold | $10.50 avg. | +67% |
| Median | — | — | $6 | −5% |
Capricor Shares Rise with FDA Review of Latest Duchenne Data, Eyes on August 22 Event
NEW YORK, August 14, 2026, 12:05 EDT – Capricor Therapeutics saw its stock price recover as the U.S. Food and Drug Administration reviews updated data from its Duchenne muscular dystrophy program, though the market remains cautious ahead of an expected announcement on August 22.
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds
Capricor Therapeutics jumped 7.6% to $30.01 early Monday after the company scheduled its fourth-quarter and full-year results for March 12, putting deramiocel—the company’s experimental treatment for Duchenne muscular dystrophy—back in focus. Duchenne is a genetic disorder that causes progressive muscle loss. Capricor plans to publish results after Thursday’s close and will hold its conference call at 4:30 p.m. ET.
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025
Capricor Therapeutics, Inc. has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its Duchenne muscular dystrophy cell therapy Deramiocel, the stock has exploded several hundred percent in barely two trading sessions and is now hovering around $29.96 per share.
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook
Capricor Therapeutics, Inc. has just turned into one of the wildest biotech stories of 2025.
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now
Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met both its primary and key secondary endpoints.GlobeNewswire
Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook
Capricor Therapeutics, Inc. is back in the spotlight on December 3, 2025, after announcing positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy. The news has reignited hopes for eventual U.S. approval of the therapy and sent CAPR shares sharply higher in premarket trading.Capricor Therapeutics, Inc.+1
TechStock² Updates
